Trial Profile
A phase III, single center, open label, uncontrolled study to evaluate the immunogenicity, safety and tolerability, of the Chiron meningococcal C conjugate vaccine when administered to healthy premature and non premature children at 3, 5, 11 months of age concomitantly with a hexavalent infant vaccine
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 27 Jul 2007
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group C conjugate (Primary)
- Indications Meningococcal group C infections
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Chiron Corporation; Novartis
- 05 Nov 2006 New trial record.